Neurology and Neurorehabilitation: Open Access 2025, 07, 02, 154. Commentary

Neuroimaging: Precision Diagnostics and Brain Disease Management

Tomas Reingold
Center for NeuroScience Research, Zurich University Hospital, Zurich, Switzerland

*Corresponding Authors**

Tomas Reingold
Center for NeuroScience Research, Zurich University Hospital, Zurich, Switzerland
E-mail: treingold@cnsresearch.ch

Received: 01-Apr-2025; **Accepted:** 09-May-2025; **Published:** 09-May-2025

Introduction

This review explores how Artificial Intelligence (AI) is transforming Alzheimer's disease neuroimaging by enhancing early detection and improving diagnostic accuracy. It highlights various Artificial Intelligence (AI) techniques applied to Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Computed Tomography (CT) scans, showing how these methods can identify subtle brain changes that act as early biomarkers, often before clinical symptoms fully manifest. The piece emphasizes Artificial Intelligence (AI)'s potential to integrate complex data, leading to more precise and personalized diagnostic tools.[1]

This systematic review investigates the role of various neuroimaging techniques in tracking the progression of pathology in Parkinson's Disease. It evaluates how structural and functional imaging modalities, such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), can serve as biomarkers to monitor disease advancement, assess treatment effectiveness, and predict clinical outcomes. The findings highlight promising imaging markers that reflect underlying neurodegeneration, offering valuable insights for disease management and therapeutic development.[2]

This review focuses on the application of Machine Learning to neuroimaging data in schizophrenia research. It explores how these advanced computational methods are being used to identify predictive biomarkers, improve diagnostic accuracy, and understand the complex neural underpinnings of the disorder. The article discusses various Machine Learning algorithms applied to Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), and Diffusion Tensor Imaging (DTI) data, demonstrating their potential to uncover subtle patterns that could lead to more personalized treatment strategies and better prognostication for individuals with schizophrenia.[3]

This review delves into longitudinal neuroimaging studies to identify biomarkers for disease progression in Multiple Sclerosis (MS). It evaluates how advanced Magnetic Resonance Imaging (MRI) techniques, including structural, functional, and quantitative imaging, can track changes in brain atrophy, lesion formation, and microstructural integrity over time. The paper discusses the utility of these markers for predicting disability worsening, assessing treatment response, and ultimately improving prognostic accuracy for Multiple Sclerosis (MS) patients.[4]

This review examines advanced neuroimaging techniques as biomarkers for diagnosing and prognosticating Traumatic Brain Injury (TBI). It covers the application of Diffusion Tensor Imaging (DTI), functional Magnetic Resonance Imaging (fMRI), and Quantitative Susceptibility Mapping (QSM) to detect subtle structural and functional changes often missed by conventional imaging. The article highlights how these sophisticated methods can improve the detection of diffuse axonal injury and microhemorrhages, offering critical insights into injury severity and potential long-term outcomes.[5]

This paper reviews the current state of neuroimaging biomarkers for depression, exploring how various brain imaging techniques can help in diagnosis, prediction of treatment response, and understanding the neuropathology of the disorder. It discusses structural and functional alterations observed in individuals with depression, including changes in brain connectivity and gray matter volume. The piece emphasizes the potential of these biomarkers to personalize treatment strategies and improve clinical outcomes by guiding therapeutic decisions.[6]

This systematic review investigates functional Magnetic Resonance Imaging (fMRI) studies to identify neuroimaging biomarkers for addiction. It examines how specific patterns of brain activity and connectivity, particularly in reward, control, and salience networks, are altered in individuals with substance use disorders. The article highlights the potential of these functional Magnetic Resonance Imaging (fMRI)-derived markers to inform diagnosis, predict relapse risk, and personalize treatment interventions by targeting specific neural pathways implicated in addictive behaviors.[7]

This paper reviews the application of advanced neuroimaging techniques in epilepsy, focusing on their utility as biomarkers for improved diagnosis, prognosis, and surgical planning. It discusses how methods like high-resolution Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and Magnetoencephalography (MEG) can localize epileptogenic zones, characterize structural and functional abnormalities, and predict post-surgical outcomes. The article underscores the importance of these imaging markers in refining patient selection for epilepsy surgery and enhancing therapeutic precision.[8]

This systematic review investigates the integration of Machine Learning with neuroimaging biomarkers to predict cognitive decline. It highlights

Cite this article: Reingold T,(2025) Neuroimaging: *Precision Diagnostics and Brain Disease Management. nnr* 07: 154. DOI: 1037532.nnr.2025.7.2.154

how various Artificial Intelligence (AI) algorithms, applied to structural and functional Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Diffusion Tensor Imaging (DTI) data, can identify early signs of cognitive impairment and forecast progression to dementia. The article explores the predictive power of these combined approaches, emphasizing their potential to enable earlier interventions and more precise risk stratification in individuals at risk for neurodegenerative conditions.[9]

This paper discusses the integration of various neuroimaging biomarkers as a path towards precision psychiatry. It explores how multimodal imaging data, including structural, functional, and molecular imaging, can provide a comprehensive picture of brain dysfunction in psychiatric disorders. The article outlines the promises of these biomarkers in improving diagnostic stratification, predicting treatment response, and guiding personalized interventions, while also addressing the significant challenges in translating these findings into routine clinical practice.[10]

Description

Neuroimaging biomarkers are crucial for advancing our understanding, diagnosis, and treatment of various neurological and psychiatric disorders. Recent advancements highlight the transformative role of Artificial Intelligence (AI) and Machine Learning in analyzing complex neuroimaging data. These computational methods significantly enhance the early detection and diagnostic accuracy across numerous conditions, enabling identification of subtle brain changes that often precede clinical symptom manifestation [1, 3, 9].

In Alzheimer's Disease, Artificial Intelligence (AI) techniques applied to Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Computed Tomography (CT) scans are pinpointing early biomarkers, promising more precise and personalized diagnostic tools [1]. For Parkinson's Disease, structural and functional imaging like Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) serve as essential biomarkers, monitoring disease progression, assessing treatment efficacy, and predicting clinical outcomes by reflecting underlying neurodegeneration [2]. Longitudinal neuroimaging studies, particularly using advanced Magnetic Resonance Imaging (MRI) techniques, are critical in Multiple Sclerosis (MS) for tracking changes in brain atrophy, lesion formation, and microstructural integrity over time, improving prognostic accuracy and assessing treatment response [4]. Advanced neuroimaging is also vital in epilepsy, utilizing high-resolution Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and Magnetoencephalography (MEG) to localize epileptogenic zones, characterize abnormalities, and guide surgical planning [8].

Traumatic Brain Injury (TBI) diagnosis and prognosis benefit from advanced neuroimaging techniques such as Diffusion Tensor Imaging (DTI), functional Magnetic Resonance Imaging (fMRI), and Quantitative Susceptibility Mapping (QSM). These methods detect subtle structural and functional changes, like diffuse axonal injury and microhemorrhages, which are often missed by conventional imaging, providing critical insights into injury severity and long-term outcomes [5]. In schizophrenia research, Machine Learning applied to Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), and Diffusion Tensor Imaging (DTI) data helps identify predictive biomarkers, enhance diagnostic accuracy, and unravel the disorder's complex neural underpinnings, potentially leading to personalized treatment strategies [3]. For depression, neuroimaging biomarkers, including structural and functional alterations in brain connectivity and gray matter volume, offer potential for diagnosis, prediction of treatment response, and a deeper understanding of neuropathology, guiding personalized therapeutic decisions [6].

Predicting cognitive decline significantly leverages the integration of Machine Learning with neuroimaging biomarkers. Artificial Intelligence (AI) algorithms applied to structural and functional Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Diffusion Tensor Imaging (DTI) data identify early signs of impairment and forecast progression to dementia, enabling earlier interventions and precise risk stratification [9]. In addiction, functional Magnetic Resonance Imaging (fMRI) studies identify neuroimaging biomarkers by examining altered patterns of brain activity and connectivity, particularly in reward, control, and salience networks. These markers hold promise for informing diagnosis, predicting relapse risk, and personalizing treatment interventions by targeting specific neural pathways implicated in addictive behaviors [7].

The integration of diverse neuroimaging biomarkers, encompassing multimodal structural, functional, and molecular imaging, paves the way for precision psychiatry. This holistic approach offers a comprehensive understanding of brain dysfunction in psychiatric disorders, improving diagnostic stratification, predicting treatment response, and guiding personalized interventions. While promising, translating these findings into routine clinical practice presents ongoing challenges [10]. Overall, neuroimaging, augmented by Artificial Intelligence (AI) and Machine Learning, is fundamentally reshaping the landscape of neurological and psychiatric care, moving towards more personalized and effective patient management.

Conclusion

Neuroimaging techniques are becoming essential tools for diagnosing, monitoring, and managing a wide array of neurological and psychiatric conditions. These advanced methods leverage various modalities like Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Computed Tomography (CT), functional Magnetic Resonance Imaging (fMRI), and Diffusion Tensor Imaging (DTI) to identify subtle brain changes and biomarkers. For neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease, imaging helps in early detection and tracking disease progression, leading to more precise diagnostic and prognostic insights. In Multiple Sclerosis (MS), longitudinal studies using Magnetic Resonance Imaging (MRI) effectively monitor disease advancement, while for epilepsy, advanced imaging aids in localizing epileptogenic zones and planning surgical interventions. Psychiatric disorders like schizophrenia and depression also benefit, with imaging uncovering neural underpinnings, predictive biomarkers, and guiding personalized treatment strategies. Traumatic Brain Injury (TBI) diagnosis is enhanced by detecting subtle structural damage, and functional Magnetic Resonance Imaging (fMRI) is shedding light on addiction mechanisms, predicting relapse risk, and tailoring interventions. Artificial Intelligence (AI) and Machine Learning play a pivotal role across these applications, integrating complex data to improve diagnostic accuracy and predict outcomes, notably in cognitive decline. The overarching goal is to integrate these diverse neuroimaging biomarkers into a framework for precision medicine, offering personalized interventions and ultimately improving patient out-

Cite this article: Reingold T,(2025) Neuroimaging: *Precision Diagnostics and Brain Disease Management. nnr* 07: 154. DOI: 1037532.nnr.2025.7.2.154

comes across neurological and psychiatric care, despite inherent challenges in clinical translation.

References

1. Md Safayet H, Shahriar M, Shanjida A. Artificial intelligence in Alzheimer's disease neuroimaging: *A systematic review. Ageing Res Rev.* 2024;93:101962.

2. James R L, Alex I L, Peter W S. The utility of neuroimaging for assessing pathology progression in Parkinson's disease: a systematic review. *J Neurol Neurosurg Psychiatry.* 2023;94:922-930.

3. Zihan W, Jinju W, Menglu L. Machine learning for neuroimaging in schizophrenia: *A systematic review of current trends and future directions. J Psychiatry Neurosci.* 2023;48:E145-E159.

4. Benjamin P B, Sven G S, Martin W. Neuroimaging Biomarkers of Disease Progression in Multiple Sclerosis: *A Review of Longitudinal Studies. J Clin Med.* 2022;11:7029.

5. Sarah K K, Christopher D N, Eric M L. Advanced Neuroimaging in Traumatic Brain Injury: *A Review of Biomarkers for Diagnosis and Prognosis. Front Neurol.* 2021;12:699719.

6. Bing X, Lin Z, Yuan F. Neuroimaging Biomarkers of Depression: *Current Status and Future Directions. Front Psychiatry.* 2020;11:584319.

7. Ya-Li M, Feng Y, Jie Z. Neuroimaging Biomarkers for Addiction: *A Systematic Review of fMRI Studies. Brain Sci.* 2022;12:1602.

8. Christoph S, Laura M H, Karl R S. Advanced Neuroimaging in Epilepsy: Biomarkers for Diagnosis, Prognosis, and *Surgical Planning. J Clin Med.* 2021;10:421.

9. Jianan L, Yilin S, Wenjun L. Machine Learning and Neuroimaging Biomarkers for Predicting Cognitive Decline: *A Systematic Review. Front Aging Neurosci.* 2022;14:916022.

10. Jun Soo K, Sang-Eun L, Jee Hoon R. Integrating neuroimaging biomarkers for precision psychiatry: promises and challenges. *Prog Neuropsychopharmacol Biol Psychiatry.* 2023;122:110705.

Cite this article: Reingold T,(2025) Neuroimaging: *Precision Diagnostics and Brain Disease Management. nnr* 07: 154. DOI: 1037532.nnr.2025.7.2.154